PDCD1 and neoplasm: Immune checkpoint inhibitors (ICIs) can selectively block the PD‐1/PD‐L1 signaling pathway to prevent T‐cell inactivation, thereby improving the ability of the patient's own immune cells to recognize and kill tumor antigens.